The immunopharmacologic and anti-inflammatory properties of RMI 9563 with special reference to its effect on the complement system.

The immunopharmacology of RMI 9563 - bis[3-(diethylamino)propyl]fluoranthene-3,9-dicarboxylate dihydrochloride--has been described. The compound, when given parenterally, inhibited several cell-mediated immune responses (EAE, tuberculin skin reaction, adjuvant arthritis) in rats, enhanced IgM and IgG antibody-producing cells in mice, and displayed anti-inflammatory activity in several models (carrageenan paw edema, adjuvant arthritis, direct passive Arthus reaction--a model of inflammation that is immunologically induced and complement-dependent). RMI 9563 suppressed the activation of complement in vitro by the selective inhibition of C1 esterase.